Abstracts tagged "Lipids"

Abstract Number: 0292 • ACR Convergence 2021
Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
Amir Razmjou¹, Jennifer Wang², Ani Shahbazian², Srinivasa Reddy³ and Christina Charles-Schoeman², ¹University of California Los Angeles Medical Center, Los Angeles, CA, ²Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ³David Geffen School of Meicine, UCLA, Los Angeles, CA
Background/Purpose: Lung disease in patients with rheumatoid arthritis (RA) is common and associates with significantly increased morbidity and mortality. Oxidative stress plays an important role…
Abstract Number: 571 • 2019 ACR/ARP Annual Meeting
Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry
Jina Yeo¹, Mi Ryoung Seo ¹, Hee Jung Ryu ¹, Hyo-Jin Choi ¹ and Han Joo Baek ¹, ¹Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total…
Abstract Number: 1972 • 2019 ACR/ARP Annual Meeting
Identification of Distinct Lipidomic Profiles in Synovial Membranes from Inflammatory Arthritis by Mass Spectrometry Imaging
Beatriz Rocha¹, Berta Cillero-Pastor ², Cristina Ruiz-Romero ³, Andrea Cuervo ⁴, Ron M A Heeren ², Juan Cañete ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain, A Coruña, Galicia, Spain, ²The Maastricht Multimodal Molecular Imaging Institute (M4I), Division of Imaging Mass Spectrometry, Maastricht University, The Netherlands., Maastricht, Limburg, Netherlands, ³Proteomics Group-ProteoRed/ISCIII, CIBER-BBN, Grupo de Investigación de Reumatología (GIR), INIBIC – Hospital Universitario de A Coruña, A Coruña, Spain., A Coruña, Spain, ⁴Arthritis Unit, Rheumatology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain., Barcelona, Catalonia, Spain, ⁵Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Early diagnosis of inflammatory arthritis is associated with improved patient outcomes. However, accurate diagnosis can be challenging because of their complexity and heterogeneous nature.…
Abstract Number: 100 • 2018 ACR/ARHP Annual Meeting
Glycosphingolipids and Proteins in Urine Exosomes: Potential Biomarkers of Lupus Nephritis
Tamara K. Nowling¹, Jessalyn Rodgers¹, Jim C. Oates², Michael Janech³ and Richard Drake⁴, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine/Nephrology, Medical University of South Carolina, Charleston, SC, ⁴Pharmacology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Exosomes, extracellular vesicles that are abundant in human urine and contain proteins from renal cells, are a potential source of biomarkers of renal disease…
Abstract Number: 207 • 2018 ACR/ARHP Annual Meeting
Divergent Patterns of Cardiovascular Risk in Biomarkers of Lipids and Subclinical Myocardial Injury during Increased Inflammation in Rheumatoid Arthritis
Katherine P. Liao¹, Jie Huang², Gabrielle Cremone³, Ethan Lam³, Nicole Yang¹, Martin Playford⁴, Christine K Iannaccone¹, Jonathan Coblyn⁵, Elena Massarotti¹, Michael E Weinblatt⁵, Nancy A. Shadick¹, Nehal Mehta⁴ and Jorge Plutzky¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴NHLBI, Bethesda, MD, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Inflammation is an independent risk factor for cardiovascular (CV) risk in rheumatoid arthritis (RA). Paradoxically, potentially cardioprotective decreases in inflammation is associated with increased…
Abstract Number: 517 • 2018 ACR/ARHP Annual Meeting
Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases
Silvia Rollefstad¹, Mona Svanteson², Nils Einar Kløw^2,3, Jonny Hisdal⁴, Eirik Ikdahl⁵, Joseph Sexton⁶, Ylva Haig² and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Division of Radiology and Nuclear Medicine, Oslo University Hospital, Ullevål, Oslo, Norway, ³Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁴Department of Vascular investigations, Oslo University Hospital, Aker, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Effects of Statin-treatment on Coronary Plaques in Patients with Inflammatory Joint DiseasesBackground/Purpose: Statins have an established preventive effect on coronary artery disease in the general…
Abstract Number: 1511 • 2018 ACR/ARHP Annual Meeting
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
Christina Charles-Schoeman¹, Gregory St. John², Henry Leher², Toshio Kimura², Hubert van Hoogstraten³, Michael T. Nurmohamed⁴, Miguel Angel González-Gay⁵ and Edward C. Keystone⁶, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴VU University Medical Center, Amsterdam, Netherlands, ⁵University Hospital Marques de Valdecilla, Santander, Spain, ⁶University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Sarilumab showed superiority to placebo and adalimumab in Phase 3 trials. Serum lipids may be reduced in the setting of chronic inflammation associated with…
Abstract Number: 1512 • 2018 ACR/ARHP Annual Meeting
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Gurjit Kaeley², Jennifer Wang³, Ani Shahbazian³, Jenny Brook⁴, David Elashoff⁴ and Veena K. Ranganath⁵, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UF Health Jacksonville, Jacksonville, FL, ³University of California, Los Angeles, Los Angeles, CA, ⁴Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Musculoskeletal ultrasound (MSUS) can detect synovitis by Power doppler (PDUS) and can predict erosive progression on xrays in rheumatoid arthritis (RA) patients. We previously…
Abstract Number: 1629 • 2018 ACR/ARHP Annual Meeting
Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
María Carmen García-Gómez¹, Maria Auxiliadora Martin², Cristina Fernández-Carballido³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, María José González-Fernández⁷, Raimon Sanmarti⁸, Alberto Garcia-Vadillo⁹, Benjamin Fernandez Gutierrez¹⁰, Miriam García-Arias¹¹, Javier Manero¹², José Miguel Senabre¹³, Amalia Rueda Cid¹⁴, Sergio Ros Expósito¹⁵, José Manuel Pina Salvador¹⁶, Alba Erra Durán¹⁷, Ingrid Moller¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay²⁰, ¹Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Institut Dexeus, Barcelona, Spain, ⁸Rheumatology Service, Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, ¹²Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹³Rheumatology, Hospital Marina Baixa, Alicante, Spain, ¹⁴Rheumatology, Hospital General de Valencia, Valencia, Spain, ¹⁵Rheumatology, Hospital de Viladecans, Barcelona, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁷Rheumatology, Hospital de Sant Rafael, Barcelona, Spain, ¹⁸Instituto de Poal, Barcelona, Spain, ¹⁹Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, ²⁰School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Cardiovascular disease (CVD) is one of the main cause of mortality and morbidity in patients with spondyloarthritis (SpA), partially explained by traditional CV risk…
Abstract Number: 1861 • 2018 ACR/ARHP Annual Meeting
Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis
Nikila Kumar¹, Wei-Hsuan Lo-Ciganic², Lili Zhou^3,4, Erin L. Ashbeck⁴ and C. Kent Kwoh^1,4, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ³College of Pharmacy, University of Arizona, Tucson, AZ, ⁴University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: Patients with RA have an increased risk of cardiovascular disease (CVD) accounting for over 50% of premature deaths in the RA population. EULAR recommends…
Abstract Number: 548 • 2017 ACR/ARHP Annual Meeting
LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis
Matthew Loza¹, Androniki Bili², Shruti Daga³, Kurt Brown⁴, Jennifer Gilbride⁵, Bidisha Dasgupta², Benjamin Hsu² and Iain B. McInnes⁶, ¹Janssen Research & Development, LLC, Springhouse, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³GlaxoSmithKline, Uxbridge, United Kingdom, ⁴GlaxoSmithKline, Collegeville, PA, ⁵Sum of Squares Ltd, Hertfordshire, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in RA in the phase…
Abstract Number: 549 • 2017 ACR/ARHP Annual Meeting
Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
Bidisha Dasgupta¹, Matthew Loza¹, Androniki Bili¹, Shruti Daga², Kurt Brown³, Jennifer Gilbride⁴, Benjamin Hsu¹ and Iain B. McInnes⁵, ¹Janssen Research & Development, LLC, Spring House, PA, ²GlaxoSmithKline, Uxbridge, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴Sum of Squares Ltd, Hertfordshire, United Kingdom, ⁵University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Understanding interactions of inflammatory cytokines and lipid metabolism in RA is of considerable interest. Blocking IL-6 receptor elevates lipid levels in RA while lowering…
Abstract Number: 913 • 2017 ACR/ARHP Annual Meeting
High Erythrocyte Levels of the n-6 Polyunsaturated Fatty Acid Linoleic Acid Are Associated with Lower Risk of Subsequent Rheumatoid Arthritis in a Southern European Nested Case-Control Study
Paola de Pablo¹, Dora Romaguera^2,3, Helena Fisk⁴, Philip Calder⁴, Anne-Marie Quirke⁵, Alison Cartwright⁵, Salvatore Panico⁶, Amalia Mattiello⁶, Diana Gavrila⁷, Carmen Navarro⁷, Carlotta Sacerdote⁸, Paolo Vineis^2,9, Rosario Tumino¹⁰, William Ollier¹¹, Dominique Michaud^2,12, Elio Riboli², Patrick Venables⁵ and Benjamin Fisher¹³, ¹University of Birmingham, Birmingham, United Kingdom, ²Imperial College London, London, United Kingdom, ³CIBER-OBN (Fisiopatología de la Obesidad y Nutrición), University Hospital Son Espases, Palma, Spain, ⁴University of Southampton, Southampton, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶Federico II University of Naples, Naples, Italy, ⁷Murcia Regional Health Council, Murcia, Spain, ⁸Città della Salute e della Scienza University-Hospital, Turin, Italy, ⁹Human Genetics Foundation, Turin, Italy, ¹⁰"Civic - M.P.Arezzo" Hospital, Ragusa, Italy, ¹¹Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹²Tufts University Medical School, Boston, MA, ¹³Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Long-chain n-3 (also known as omega-3) polyunsaturated fatty acids (PUFA), especially eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), have long-been considered to…
Abstract Number: 1265 • 2017 ACR/ARHP Annual Meeting
Impaired Cardiac Function in Juvenile Mixed Connective Tissue Disease Compared with Controls
Birgit Nomeland Witczak¹, Siri Opsahl Hetlevik², Zoltan Barth^1,3, Thomas Schwartz^4,5, Berit Flatø^2,6, Vibke Lilleby^2,6 and Ivar Sjaastad^1,6,7, ¹Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Department of Pathophysiology and Gerontology, Medical School, University of Pècs, Pècs, Hungary, Pècs, Hungary, ⁴Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, ⁵Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁷Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Juvenile MCTD (JMCTD) is a heterogenic autoimmune disease, with SLE-, SSc- and PM/DM and RA like manifestations. Cardiac involvement is known in juvenile SLE,…
Abstract Number: 2328 • 2017 ACR/ARHP Annual Meeting
Characterisation of Lipid Mediator Profile and Immune Cells in Synovial Fluid of Juvenile Idiopathic Arthritis
Johannes Hendrick von Hegedus¹, Q. S. R. Madari², P.C.E. Hissink Muller³, M. Kloppenburg⁴, REM Toes⁴, Martin Giera⁵, TWJ Huizinga⁴, Rebecca ten Cate⁶ and A. Ioan-Facsinay⁴, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Willem-Alexander Children's Hospital, LUMC, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is often accompanied by inflammation of the joints. The mechanisms involved in the inflammation in JIA are incompletely understood. Several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].